晚期上皮性卵巢癌腹膜后淋巴结清扫的临床价值

许冬娣; 汪艳

doi:10.7619/jcmp.201309062

晚期上皮性卵巢癌腹膜后淋巴结清扫的临床价值

许冬娣,
汪艳

安徽省安庆市立医院妇产科,安徽安庆,246003

基金项目: 中国高校医学期刊临床专项资金

详细信息

中图分类号: R737.31
计量
- 文章访问数: 140
- HTML全文浏览量: 26
- PDF下载量: 0
出版历程
- 发布日期: 2013-10-17

Clinical value of retroperitoneal lymph nodes dissection on advanced epithelial ovarian cancer

XU Dongdi,
WANG Yan

摘要

摘要: 目的评价腹膜后淋巴结清扫对晚期上皮性卵巢癌预后的影响.方法将67例晚期上皮性卵巢癌患者随机分为研究组32例及对照组35例.研究组行卵巢肿瘤细胞减灭术+术后规范化疗,对照组行卵巢肿瘤细胞减灭术+腹膜后淋巴结清扫术+术后规范化疗,对比2组手术时间、术中出血量、术后病率及术后1、3、5年生存率的差异.结果研究组术中出血量、手术时间、术后病率均显著小于对照组.2组1、3、5年生存率均无显著差异；而2组术后残留癌灶＜1.0 cm的患者3、5年生存率均显著高于同组残留癌灶≥1.0cm的患者.结论理想的肿瘤减灭术是影响晚期上皮性卵巢癌患者预后的重要因素,而腹膜后淋巴结清扫不能提高晚期上皮性卵巢癌的生存率,反而使围手术期的并发症显著提高.
- 晚期上皮性卵巢癌 /
- 腹膜后淋巴结清扫 /
- 术后残留癌灶 /
- 生存率
- advanced epithelial ovarian cancer /
- retroperitoneal lymph nodes dissection /
- postoperative residual cancer focus /
- survival rate

HTML全文

参考文献(16)

乐杰. 妇产科学 [M]. 北京:人民卫生出版社, 2007.282.

Gaitskell K, Martinek I, Bryant A. Angiogenesis inhibitors for the treatment of ovarian cancer [J]. Cochrane Database of Systematic Reviews, 2011(9):CD007930.

Vergote I, Tropé C G, Amant F. Neoadjuvant chemotherapy or primary surgery in stage Ⅲ C or Ⅳ ovarian cancer [J]. New England Journal of Medicine, 2010, (10):943.

Ang C, Chan K K, Bryant A. Ultra-radical (extensive) surgery versus standard surgery for the primary cytoreduction of advanced epithelial ovarian cancer [J]. Cochrane Database of Systematic Reviews, 2011(4):CD007697.

Powless C A, Aletti G D, Bakkum-Gamez J N. Risk factors for lymph node metastasis in apparent early-stage epithelial ovarian cancer:implications for surgical staging [J]. Gynecologic Oncology, 2011(3):536.

Elattar A, Bryant A, Winter-Roach B A. Optimal primary surgical treatment for advanced epithelial ovarian cancer [J]. Cochrane Database of Systematic Reviews, 2011(8):CD007565.

Al Rawahi T, Lopes A D, Bristow R E. Surgical cytoreduction for recurrent epithelial ovarian cancer [J]. Cochrane Database of Systematic Reviews, 2013.CD008765.

Aletti G D, Dowdy SC, Gostout BS. Aggressive surgical effort and improved survival in advanced-stage ovarian cancer [J]. Obstetrics and Gynecology, 2006(1):77.

Aletti G D, Cliby W A. Importance of surgical aggressiveness in advanced ovarian cancer [J]. Journal of Clinical Oncology, 2006, (15):2397.

Panici P B, Maggioni A, Hacker N. Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer:a randomized clinical trial [J]. Journal of the National Cancer Institute, 2005(8):560.

Benedetti Panici P, Basile S, Maneschi F. Systematic pelvic lymphadenectomy vs.no lymphadenectomy in earlystage endometrial carcinoma:randomized clinical trial [J]. Journal of the National Cancer Institute, 2008, (23):1707.

Bristow R E, Tomacruz R S, Armstrong D K. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era:a meta-analysis [J]. Journal of Clinical Oncology, 2002(5):1248.

谢守珍, 宋成文, 王晶. 卵巢癌术后化疗联合醋酸甲羟孕酮抑制盆腔病理血管生成的研究 [J]. 华南国防医学杂志, 2008(5):33.

段振玲, 彭芝兰, 王赞宏. 自噬基因Beclin1对上皮性卵巢癌细胞SKOV3生长的抑制作用 [J]. 南方医科大学学报, 2010(4):672.

仲召阳, 卿毅, 李梦侠. Bayes法建立卵巢癌多肿瘤标志物判别函数及临床意义 [J]. 华南国防医学杂志, 2009(1):24.

施引文献

资源附件(0)

计量

文章访问数: 140
HTML全文浏览量: 26
PDF下载量: 0
被引次数: 0

晚期上皮性卵巢癌腹膜后淋巴结清扫的临床价值

计量

出版历程

Clinical value of retroperitoneal lymph nodes dissection on advanced epithelial ovarian cancer

计量

出版历程

目录